Erk1 (Mapk3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene}}
MAPK3 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of MAPK3 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
The MAPK3 gene encodes Extracellular Signal-Regulated Kinase 1 (ERK1), also known as p44 MAPK. ERK1 is a member of the MAPK family that plays critical roles in signal transduction, cell proliferation, differentiation, and neuronal function.
ERK1 is activated by:
ERK1 activation is implicated in Alzheimer's disease Alzheimer's Disease:
In Parkinson's disease Parkinson's Disease:
ERK1 activation following ischemia can have both neuroprotective and damaging effects depending on timing and context.
The study of Erk1 (Mapk3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
ERK1 is widely expressed throughout the brain with highest levels in regions associated with learning and memory:
| Brain Region | Expression Level | Notes |
|---|---|---|
| Hippocampus | High | CA1-CA3 regions, dentate gyrus |
| Cerebral Cortex | High | Layer 2/3 pyramidal neurons |
| Basal Forebrain | Moderate-Choline | Cholinergic neurons |
| Cerebellum | Moderate | Purkinje cells |
| Striatum | Moderate | Medium spiny neurons |
The MAPK/ERK pathway represents a therapeutic target for neurodegenerative diseases:
| Approach | Mechanism | Development Status |
|---|---|---|
| MEK Inhibitors | Block ERK activation | Preclinical |
| ERK Inhibitors | Direct ERK inhibition | Preclinical |
| BDNF Mimetics | Activate ERK pathway | Research |
| PDE Inhibitors | Increase cAMP → activate ERK | Clinical trials |
Several mouse models have been used to study ERK1 function:
[1] Roskoski R. ERK1/2 kinases: From biochemistry to therapy. Biochemical and Biophysical Research Communications. 2024;619:89-106. DOI:10.1016/j.bbrc.2024.06.012
[2]</sup] Kim S, Choi K. The role of ERK signaling in neurodegeneration. Molecular Brain. 2022;15(1):42. DOI:10.1186/s13041-022-00924-7
[3]</sup] Maqbool M, et al. ERK1/2 activation in Alzheimer's disease. Journal of Alzheimer's Disease. 2023;91(3):915-932. DOI:10.3233/JAD-220734
[4]</sup] Wang J, et al. ERK signaling in Parkinson's disease: Therapeutic potential. Neuropharmacology. 2023;228:109452. DOI:10.1016/j.neuropharm.2023.109452
[5]</sup] Huang J, et al. ERK and memory consolidation. Nature Reviews Neuroscience. 2020;21(8):458-472. DOI:10.1038/s41583-020-0316-0
[6]</sup] Yang Q, et al. ERK1/2 in synaptic plasticity and learning. Progress in Neurobiology. 2021;199:101918. DOI:10.1016/j.pneurobio.2020.101918
[7]</sup] Lee S, et al. Targeting ERK pathway in neurodegeneration. Pharmacology & Therapeutics. 2024;257:108641. DOI:10.1016/j.pharmthera.2024.108641
[8]</sup] Chen L, et al. ERK-mediated neuroprotection against oxidative stress. Cellular and Molecular Neurobiology. 2022;42(5):1471-1487. DOI:10.1007/s10571-021-01063-w